Cytokinetics challenges Bristol Myers Squibb with newly approved heart disease drug

Cytokinetics Inc.'s drug for the treatment of obstructive hypertrophic cardiomyopathy has been approved in the United States and will be sold under the brand name Myqorzo. The U.S. Food and Drug Administration (FDA) has issued a black box warning regarding its potential risk of causing heart failure, and Myqorzo will only be available to patients through a restricted program. This approval marks the beginning of competition between Cytokinetics and Bristol Myers Squibb Co., which has a similar therapy named Camzyos—considered a key contributor to the company's future growth